In addition, a subset of IDH1mut gliomas that recur and subsequently demonstrate rapid growth phenotypes have been shown to produce far lower levels of D-2-HG even while retaining IDH1 mutations (65). This evidence concerns the gene IDH1 and central nervous system cancer.